ELXR
Dead / Abandoned — Abandoned — failure to respond (as of 02 Jul 2023)
What this means for you
This application is over — abandoned 15 Jun 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97761835
- Mark type
- Stylized text
- Filed
- 20 Jan 2023
- Abandoned
- 15 Jun 2023
- Attorney of record
- John Paul Oleksiuk
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, pain, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, pain, and also cardiovascular, peripheral nervous system, cancer, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, hematologic and viral or bacterial diseases and disorders
Owner
- Scribe Therapeutics Inc., Alameda, CA, US
Prosecution history
- 03 Jul 2023 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 02 Jul 2023 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
- 02 Jul 2023 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 14 Mar 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 14 Mar 2023 — NON-FINAL ACTION E-MAILED
- 14 Mar 2023 — NON-FINAL ACTION WRITTEN
- 09 Mar 2023 — ASSIGNED TO EXAMINER
- 26 Jan 2023 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 24 Jan 2023 — NEW APPLICATION ENTERED